Company intelligence / Profile preview

PanOptica

Mount Arlington, New Jersey, United Statespanoptica.app ↗

Ownership: Private
Employees: ~15
Development stage: Commercial

Overview

PanOptica’s lead compound, PAN-90806, is a novel small-molecule selective VEGF receptor antagonist being developed as a topical eye drop for the treatment of neovascular age-related macular degeneration and other sight-threatening eye diseases. Clinical development has reached Phase 2 for wet AMD. The company is also developing additional assets such as PAN-90716-DES for broader eye disease indications[1][4].

Therapeutic areas: Ophthalmology
Modalities: Small molecule
Industry: Biotech

Drug pipeline

1 asset

PAN-90806

Partnerships

No major pharmaceutical partnerships publicly disclosed; investors include SV Life Sciences and Novo A/S

Beyond the preview

Go deeper on PanOptica.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on PanOptica.

Explore the full profile